Skip to main content
Top
Published in: Archives of Virology 10/2019

01-10-2019 | Human Immunodeficiency Virus | Original Article

High prevalence of occult hepatitis C virus infection in injection drug users with HIV infection

Authors: Tahereh Donyavi, Farah Bokharaei-Salim, Khadijeh Khanaliha, Maryam Sheikh, Mohammad-Navid Bastani, Najmeh Moradi, Roghayeh Babaei, Zahra Habib, Atousa Fakhim, Maryam Esghaei

Published in: Archives of Virology | Issue 10/2019

Login to get access

Abstract

One of the pathological forms of chronic hepatitis C is occult HCV infection (OCI), in which there is no detectable HCV RNA in plasma specimens but HCV RNA is present in PBMCs and liver biopsy specimens. The aim of this study is to estimate the prevalence of OCI in HIV-positive people who are injection drug users (IDUs). From April 2015 to August 2018, 161 Iranian IDUs with HIV infection enrolled in the study. Viral RNA was extracted from plasma and PBMC samples of participants, and the presence of HCV RNA was examined using RT nested PCR with primers from two conserved regions (5´-UTR and NS5B). HCV genotyping was performed using RFLP and sequencing methods. Of the 161 patients, 134 (83.2%) were positive for anti-HCV antibodies. All 27 patients who were negative for anti-HCV were also negative for HCV RNA in plasma, but five of them (18.5%) were positive for HCV RNA in PBMCs. Importantly, 9 out of 50 patients (18.0%) who apparently had recovered from HCV infection (i.e., were anti-HCV positive and HCV RNA negative) were positive for HCV RNA in PBMCs. Overall, 18.1% of the patients who had no signs of previous HCV infection or had apparently recovered from the disease had OCI. The HCV genotypes of the cases with OCI were as follows: five patients (35.7%) were infected with subtype 1a, eight patients (57.1%) were infected with subtype 3a, and one patient (7.1%) was infected with genotype 4. Thus, it seems that the prevalence of OCI in HIV-positive IDUs is extremely significant in Iran and is likely to delay the global eradication of HCV infection until 2030.
Literature
1.
go back to reference Kuehlkamp VM, Schuelter-Trevisol F (2013) Prevalence of human immunodeficiency virus/hepatitis C virus co-infection in Brazil and associated factors: a review. Braz J Infect Dis 17(4):455–463CrossRefPubMed Kuehlkamp VM, Schuelter-Trevisol F (2013) Prevalence of human immunodeficiency virus/hepatitis C virus co-infection in Brazil and associated factors: a review. Braz J Infect Dis 17(4):455–463CrossRefPubMed
4.
go back to reference Khodabandehloo M, Roshani D, Sayehmiri K (2013) Prevalence and trend of hepatitis C virus infection among blood donors in Iran: a systematic review and meta-analysis. J Res Med Sci 18(8):674–682PubMedPubMedCentral Khodabandehloo M, Roshani D, Sayehmiri K (2013) Prevalence and trend of hepatitis C virus infection among blood donors in Iran: a systematic review and meta-analysis. J Res Med Sci 18(8):674–682PubMedPubMedCentral
5.
go back to reference Castillo I, Pardo M, Bartolome J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S et al (2004) Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 189(1):7–14CrossRefPubMed Castillo I, Pardo M, Bartolome J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S et al (2004) Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 189(1):7–14CrossRefPubMed
6.
go back to reference Di Liberto G, Roque-Afonso AM, Kara R, Ducoulombier D, Fallot G, Samuel D et al (2006) Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology 131(1):76–84CrossRefPubMed Di Liberto G, Roque-Afonso AM, Kara R, Ducoulombier D, Fallot G, Samuel D et al (2006) Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology 131(1):76–84CrossRefPubMed
7.
go back to reference Vidimliski PD, Nikolov I, Geshkovska NM, Dimovski A, Rostaing L, Sikole A (2014) Review: occult hepatitis C virus infection: still remains a controversy. J Med Virol 86(9):1491–1498CrossRefPubMed Vidimliski PD, Nikolov I, Geshkovska NM, Dimovski A, Rostaing L, Sikole A (2014) Review: occult hepatitis C virus infection: still remains a controversy. J Med Virol 86(9):1491–1498CrossRefPubMed
8.
go back to reference Gad YZ, Ahmad NA, Mousa N, Farag RE, Abdel-Aziz AA, Abousmra NM et al (2012) Occult hepatitis C infection: the prevalence and profile of its immunoregulatory cytokines. Egypt Liver J 2(4):108–112CrossRef Gad YZ, Ahmad NA, Mousa N, Farag RE, Abdel-Aziz AA, Abousmra NM et al (2012) Occult hepatitis C infection: the prevalence and profile of its immunoregulatory cytokines. Egypt Liver J 2(4):108–112CrossRef
9.
go back to reference Mousa N, Eldars W, Eldegla H, Fouda O, Gad Y, Abousamra N et al (2014) Cytokine profiles and hepatic injury in occult hepatitis C versus chronic hepatitis C virus infection. Int J Immunopathol Pharmacol 27(1):87–96CrossRefPubMed Mousa N, Eldars W, Eldegla H, Fouda O, Gad Y, Abousamra N et al (2014) Cytokine profiles and hepatic injury in occult hepatitis C versus chronic hepatitis C virus infection. Int J Immunopathol Pharmacol 27(1):87–96CrossRefPubMed
10.
go back to reference Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ (2004) HIV and hepatitis C coinfection within the CAESAR study. HIV Med 5(3):174–179CrossRefPubMed Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ (2004) HIV and hepatitis C coinfection within the CAESAR study. HIV Med 5(3):174–179CrossRefPubMed
11.
go back to reference Mohammadi M, Talei G, Sheikhian A, Ebrahimzade F, Pournia Y, Ghasemi E et al (2009) Survey of both hepatitis B virus (HBsAg) and hepatitis C virus (HCV-Ab) coinfection among HIV positive patients. Virol J 6:202CrossRefPubMedPubMedCentral Mohammadi M, Talei G, Sheikhian A, Ebrahimzade F, Pournia Y, Ghasemi E et al (2009) Survey of both hepatitis B virus (HBsAg) and hepatitis C virus (HCV-Ab) coinfection among HIV positive patients. Virol J 6:202CrossRefPubMedPubMedCentral
12.
go back to reference SeyedAlinaghi S, Jam S, Mehrkhani F, Fattahi F, Sabzvari D, Kourorian Z et al (2011) Hepatitis-C and hepatitis-B co-infections in patients with human immunodeficiency virus in Tehran, Iran. Acta Medica Iranica 49(4):252PubMed SeyedAlinaghi S, Jam S, Mehrkhani F, Fattahi F, Sabzvari D, Kourorian Z et al (2011) Hepatitis-C and hepatitis-B co-infections in patients with human immunodeficiency virus in Tehran, Iran. Acta Medica Iranica 49(4):252PubMed
13.
go back to reference Malekinejad M, Navadeh S, Lotfizadeh A, Rahimi-Movaghar A, Amin-Esmaeili M, Noroozi A (2015) High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001–2012). Int J Infect Dis 40:116–130CrossRefPubMedPubMedCentral Malekinejad M, Navadeh S, Lotfizadeh A, Rahimi-Movaghar A, Amin-Esmaeili M, Noroozi A (2015) High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001–2012). Int J Infect Dis 40:116–130CrossRefPubMedPubMedCentral
14.
go back to reference Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C et al (2016) Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 16(7):797–808CrossRefPubMed Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C et al (2016) Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 16(7):797–808CrossRefPubMed
15.
go back to reference Kim AY, Onofrey S, Church DR (2013) An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection. J Infect Dis 207(suppl_1):S1–S6CrossRefPubMedPubMedCentral Kim AY, Onofrey S, Church DR (2013) An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection. J Infect Dis 207(suppl_1):S1–S6CrossRefPubMedPubMedCentral
16.
go back to reference Pohjanpelto P, Lappalainen M, Widell A, Asikainen K, Paunio M (1996) Hepatitis C genotypes in Finland determined by RFLP. Clin Diagn Virol 7(1):7–16CrossRefPubMed Pohjanpelto P, Lappalainen M, Widell A, Asikainen K, Paunio M (1996) Hepatitis C genotypes in Finland determined by RFLP. Clin Diagn Virol 7(1):7–16CrossRefPubMed
17.
go back to reference Ji H, Kozak RA, Biondi MJ, Pilon R, Vallee D, Liang BB et al (2015) Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology 477:1–9CrossRefPubMed Ji H, Kozak RA, Biondi MJ, Pilon R, Vallee D, Liang BB et al (2015) Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology 477:1–9CrossRefPubMed
18.
go back to reference Zaghloul H, El-Sherbiny W (2010) Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Investig 39(3):284–291CrossRef Zaghloul H, El-Sherbiny W (2010) Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Investig 39(3):284–291CrossRef
19.
go back to reference Idrees M, Lal A, Malik FA, Hussain A, Rehman I, Akbar H et al (2011) Occult hepatitis C virus infection and associated predictive factors: the Pakistan experience. Infect Genet Evol 11(2):442–445CrossRefPubMed Idrees M, Lal A, Malik FA, Hussain A, Rehman I, Akbar H et al (2011) Occult hepatitis C virus infection and associated predictive factors: the Pakistan experience. Infect Genet Evol 11(2):442–445CrossRefPubMed
20.
go back to reference Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Nassiri Toosi M, Fakhim S et al (2013) Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon 13(8):e11290CrossRefPubMedPubMedCentral Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Nassiri Toosi M, Fakhim S et al (2013) Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon 13(8):e11290CrossRefPubMedPubMedCentral
21.
go back to reference Bastani MN, Bokharaei-Salim F, Keyvani H, Esghaei M, Monavari SH, Ebrahimi M et al (2016) Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major. Arch Virol 161(7):1899–1906CrossRefPubMed Bastani MN, Bokharaei-Salim F, Keyvani H, Esghaei M, Monavari SH, Ebrahimi M et al (2016) Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major. Arch Virol 161(7):1899–1906CrossRefPubMed
22.
go back to reference Kahyesh-Esfandiary R, Sadigh ZA, Esghaei M, Bastani MN, Donyavi T, Najafi A et al (2019) Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta-thalassemia major: occult HCV infection. J Med Virol 91(1):107–114CrossRefPubMed Kahyesh-Esfandiary R, Sadigh ZA, Esghaei M, Bastani MN, Donyavi T, Najafi A et al (2019) Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta-thalassemia major: occult HCV infection. J Med Virol 91(1):107–114CrossRefPubMed
23.
go back to reference Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernandez N et al (2008) Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 19(12):2288–2292CrossRefPubMedPubMedCentral Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernandez N et al (2008) Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 19(12):2288–2292CrossRefPubMedPubMedCentral
24.
go back to reference El-shishtawy S, Sherif N, Abdallh E, Kamel L, Shemis M, Saleem AAA et al (2015) Occult hepatitis C virus infection in hemodialysis patients; Single Center Study. Electron Physician 7(8):1619–1625CrossRefPubMedPubMedCentral El-shishtawy S, Sherif N, Abdallh E, Kamel L, Shemis M, Saleem AAA et al (2015) Occult hepatitis C virus infection in hemodialysis patients; Single Center Study. Electron Physician 7(8):1619–1625CrossRefPubMedPubMedCentral
25.
go back to reference Naghdi R, Ranjbar M, Bokharaei-Salim F, Keyvani H, Savaj S, Ossareh S et al (2017) Occult hepatitis C infection among hemodialysis patients: a prevalence study. Ann Hepatol 16(4):510–513CrossRefPubMed Naghdi R, Ranjbar M, Bokharaei-Salim F, Keyvani H, Savaj S, Ossareh S et al (2017) Occult hepatitis C infection among hemodialysis patients: a prevalence study. Ann Hepatol 16(4):510–513CrossRefPubMed
26.
go back to reference Baid-Agrawal S, Berg T (2014) Reply to: “underestimation of occult hepatitis C virus infection in chronic haemodialysis and kidney transplant patients”. J Hepatol 61(5):1185–1186CrossRefPubMed Baid-Agrawal S, Berg T (2014) Reply to: “underestimation of occult hepatitis C virus infection in chronic haemodialysis and kidney transplant patients”. J Hepatol 61(5):1185–1186CrossRefPubMed
27.
go back to reference Castillo I, Martinez-Ara J, Olea T, Bartolomé J, Madero R, Hernández E et al (2014) High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int 86(3):619–624CrossRefPubMed Castillo I, Martinez-Ara J, Olea T, Bartolomé J, Madero R, Hernández E et al (2014) High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int 86(3):619–624CrossRefPubMed
28.
go back to reference Makvandi M, Khalafkhany D, Rasti M, Neisi N, Omidvarinia A, Mirghaed A et al (2014) Detection of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with abnormal alanine transaminase in Ahvaz. Indian J Med Microbiol 32(3):251CrossRefPubMed Makvandi M, Khalafkhany D, Rasti M, Neisi N, Omidvarinia A, Mirghaed A et al (2014) Detection of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with abnormal alanine transaminase in Ahvaz. Indian J Med Microbiol 32(3):251CrossRefPubMed
29.
go back to reference Helaly GF, Elsheredy AG, El Basset Mousa AA, Ahmed HK, Oluyemi AE (2017) Seronegative and occult hepatitis C virus infections in patients with hematological disorders. Arch Virol 162(1):63–69CrossRefPubMed Helaly GF, Elsheredy AG, El Basset Mousa AA, Ahmed HK, Oluyemi AE (2017) Seronegative and occult hepatitis C virus infections in patients with hematological disorders. Arch Virol 162(1):63–69CrossRefPubMed
30.
go back to reference Youssef SS, Nasr AS, El Zanaty T, El Rawi RS, Mattar MM (2012) Prevalence of occult hepatitis C virus in egyptian patients with chronic lymphoproliferative disorders. Hepat Res Treat 2012:429784PubMedPubMedCentral Youssef SS, Nasr AS, El Zanaty T, El Rawi RS, Mattar MM (2012) Prevalence of occult hepatitis C virus in egyptian patients with chronic lymphoproliferative disorders. Hepat Res Treat 2012:429784PubMedPubMedCentral
31.
go back to reference Roque Cuéllar M, García Lozano J, Sánchez B, Carrillo Cruz E, De la Cruz Vicente F (2017) Occult hepatitis C virus infection in Spanish patients with lymphoproliferative disorders. J Emerg Dis Virol 3(2):2473 (1846.134) Roque Cuéllar M, García Lozano J, Sánchez B, Carrillo Cruz E, De la Cruz Vicente F (2017) Occult hepatitis C virus infection in Spanish patients with lymphoproliferative disorders. J Emerg Dis Virol 3(2):2473 (1846.134)
32.
go back to reference Farahani M, Bokharaei-Salim F, Ghane M, Basi A, Meysami P, Keyvani H (2013) Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders. J Med Virol 85(2):235–240CrossRefPubMed Farahani M, Bokharaei-Salim F, Ghane M, Basi A, Meysami P, Keyvani H (2013) Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders. J Med Virol 85(2):235–240CrossRefPubMed
33.
go back to reference Abdelrahim SS, Khairy R, Esmail MAM, Ragab M, Abdel-Hamid M, Abdelwahab SF (2016) Occult hepatitis C virus infection among Egyptian hemodialysis patients. J Med Virol 88(8):1388–1393CrossRefPubMed Abdelrahim SS, Khairy R, Esmail MAM, Ragab M, Abdel-Hamid M, Abdelwahab SF (2016) Occult hepatitis C virus infection among Egyptian hemodialysis patients. J Med Virol 88(8):1388–1393CrossRefPubMed
34.
go back to reference De Marco L, Gillio-Tos A, Fiano V, Ronco G, Krogh V, Palli D et al (2009) Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PloS One. 4(12):e8128CrossRefPubMedPubMedCentral De Marco L, Gillio-Tos A, Fiano V, Ronco G, Krogh V, Palli D et al (2009) Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PloS One. 4(12):e8128CrossRefPubMedPubMedCentral
35.
go back to reference De Marco L, Manzini P, Trevisan M, Gillio-Tos A, Danielle F, Balloco C et al (2012) Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease. PloS One. 7(8):e43541CrossRefPubMedPubMedCentral De Marco L, Manzini P, Trevisan M, Gillio-Tos A, Danielle F, Balloco C et al (2012) Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease. PloS One. 7(8):e43541CrossRefPubMedPubMedCentral
36.
go back to reference Lin H, Chen X, Zhu S, Mao P, Zhu S, Liu Y et al (2016) Prevalence of occult hepatitis C virus infection among blood donors in Jiangsu, China. Intervirology 59(4):204–210CrossRefPubMed Lin H, Chen X, Zhu S, Mao P, Zhu S, Liu Y et al (2016) Prevalence of occult hepatitis C virus infection among blood donors in Jiangsu, China. Intervirology 59(4):204–210CrossRefPubMed
37.
go back to reference Gatserelia L, Sharvadze L, Karchava M, Dolmazashvili E, Tsertsvadze T (2014) Occurrence of occult HCV infection among HIV infected patients in Georgia. Georgian Med News 226:37–41 Gatserelia L, Sharvadze L, Karchava M, Dolmazashvili E, Tsertsvadze T (2014) Occurrence of occult HCV infection among HIV infected patients in Georgia. Georgian Med News 226:37–41
38.
go back to reference Bokharaei-Salim F, Keyvani H, Esghaei M, Zare-Karizi S, Dermenaki-Farahani S-S, Hesami-Zadeh K et al (2016) Prevalence of occult hepatitis C virus infection in the Iranian patients with human immunodeficiency virus infection. J Med Virol 88(11):1960–1966CrossRefPubMed Bokharaei-Salim F, Keyvani H, Esghaei M, Zare-Karizi S, Dermenaki-Farahani S-S, Hesami-Zadeh K et al (2016) Prevalence of occult hepatitis C virus infection in the Iranian patients with human immunodeficiency virus infection. J Med Virol 88(11):1960–1966CrossRefPubMed
39.
go back to reference Sheikh M, Bokharaei-Salim F, Monavari SH, Ataei-Pirkooh A, Esghaei M, Moradi N et al (2019) Molecular diagnosis of occult hepatitis C virus infection in Iranian injection drug users. Arch Virol 164(2):349–357CrossRefPubMed Sheikh M, Bokharaei-Salim F, Monavari SH, Ataei-Pirkooh A, Esghaei M, Moradi N et al (2019) Molecular diagnosis of occult hepatitis C virus infection in Iranian injection drug users. Arch Virol 164(2):349–357CrossRefPubMed
40.
go back to reference Vento S, Cainelli F, Longhi MS (2002) Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 3(6):333–340CrossRefPubMed Vento S, Cainelli F, Longhi MS (2002) Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 3(6):333–340CrossRefPubMed
41.
go back to reference Melisko ME, Fox R, Venook A (2004) Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol 16(3):204–205CrossRef Melisko ME, Fox R, Venook A (2004) Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol 16(3):204–205CrossRef
42.
go back to reference Lin A, Thadareddy A, Goldstein MJ, Lake-Bakaar G (2008) Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol 80(10):1720–1722CrossRefPubMed Lin A, Thadareddy A, Goldstein MJ, Lake-Bakaar G (2008) Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol 80(10):1720–1722CrossRefPubMed
43.
go back to reference Bartolome J, Lopez-Alcorocho JM, Castillo I, Rodriguez-Inigo E, Quiroga JA, Palacios R et al (2007) Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 81(14):7710–7715CrossRefPubMedPubMedCentral Bartolome J, Lopez-Alcorocho JM, Castillo I, Rodriguez-Inigo E, Quiroga JA, Palacios R et al (2007) Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 81(14):7710–7715CrossRefPubMedPubMedCentral
44.
45.
go back to reference Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR et al (2010) Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 14(Suppl 3):e113–e116CrossRefPubMed Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR et al (2010) Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 14(Suppl 3):e113–e116CrossRefPubMed
46.
go back to reference Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG et al (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61(1):77–87CrossRefPubMed Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG et al (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61(1):77–87CrossRefPubMed
47.
go back to reference Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61(1 Suppl):S45–S57CrossRefPubMed Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61(1 Suppl):S45–S57CrossRefPubMed
48.
go back to reference Ghaderi-Zefrehi H, Gholami-Fesharaki M, Sharafi H, Sadeghi F, Alavian SM (2016) The distribution of hepatitis C virus genotypes in middle eastern countries: a systematic review and meta-analysis. Hepat Mon 16(9):e40357CrossRefPubMedPubMedCentral Ghaderi-Zefrehi H, Gholami-Fesharaki M, Sharafi H, Sadeghi F, Alavian SM (2016) The distribution of hepatitis C virus genotypes in middle eastern countries: a systematic review and meta-analysis. Hepat Mon 16(9):e40357CrossRefPubMedPubMedCentral
49.
go back to reference Ruta S, Cernescu C (2015) Injecting drug use: a vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol 21(38):10811–10823CrossRefPubMedPubMedCentral Ruta S, Cernescu C (2015) Injecting drug use: a vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol 21(38):10811–10823CrossRefPubMedPubMedCentral
50.
go back to reference Alavian SM, Miri SM, Keshvari M, Elizee PK, Behnava B, Tabatabaei SV et al (2009) Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion 49(10):2195–2199CrossRefPubMed Alavian SM, Miri SM, Keshvari M, Elizee PK, Behnava B, Tabatabaei SV et al (2009) Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion 49(10):2195–2199CrossRefPubMed
51.
go back to reference Blackard JT, Smeaton L, Hiasa Y, Horiike N, Onji M, Jamieson DJ et al (2005) Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons. J Infect Dis 192(2):258–265CrossRefPubMed Blackard JT, Smeaton L, Hiasa Y, Horiike N, Onji M, Jamieson DJ et al (2005) Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons. J Infect Dis 192(2):258–265CrossRefPubMed
52.
go back to reference Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M et al (2013) Decreasing mortality and changing patterns of causes of death in the Swiss HIV cohort study. HIV Med 14(4):195–207CrossRefPubMed Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M et al (2013) Decreasing mortality and changing patterns of causes of death in the Swiss HIV cohort study. HIV Med 14(4):195–207CrossRefPubMed
53.
go back to reference Hsieh MH, Tsai JJ, Hsieh MY, Huang CF, Yeh ML, Yang JF et al (2014) Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. PloS One 9(4):e94791CrossRefPubMedPubMedCentral Hsieh MH, Tsai JJ, Hsieh MY, Huang CF, Yeh ML, Yang JF et al (2014) Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. PloS One 9(4):e94791CrossRefPubMedPubMedCentral
54.
go back to reference Thongsawat S, Maneekarn N, Kuniholm MH, Pantip C, Thungsuputi A, Lumlertkul D et al (2008) Occult hepatitis C virus infection during an outbreak in a hemodialysis unit in Thailand. J Med Virol 80(5):808–815CrossRefPubMed Thongsawat S, Maneekarn N, Kuniholm MH, Pantip C, Thungsuputi A, Lumlertkul D et al (2008) Occult hepatitis C virus infection during an outbreak in a hemodialysis unit in Thailand. J Med Virol 80(5):808–815CrossRefPubMed
Metadata
Title
High prevalence of occult hepatitis C virus infection in injection drug users with HIV infection
Authors
Tahereh Donyavi
Farah Bokharaei-Salim
Khadijeh Khanaliha
Maryam Sheikh
Mohammad-Navid Bastani
Najmeh Moradi
Roghayeh Babaei
Zahra Habib
Atousa Fakhim
Maryam Esghaei
Publication date
01-10-2019
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 10/2019
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-019-04353-3

Other articles of this Issue 10/2019

Archives of Virology 10/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.